T-20 (Enfuvirtide, Fuzeon) Research
- People Who Use Fuzeon May Be at 34 Percent Higher Risk for Pneumonia (May 2, 2011)
From Project Inform
On TheBodyPRO.com
- Needle-Free Mode of T-20 Dosing Looks Highly Satisfactory for Patients (August 28, 2006)
From aidsmap.com
- HIV JournalView: Disappointing Results With Once-Daily Enfuvirtide (February/March 2006)
- HIV JournalView: Enfuvirtide: Is Needleless Dosing Possible? (February/March 2006)
- Trimeris Shares Increase 13% as Sales of Fuzeon Rise in Europe, Brazil; Analysts Predict Profit as Early as 2006 (July 22, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- FDA Warns Roche About Misleading Comments Made by Salesperson Regarding Fuzeon (July 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
- Roche, Trimeris Seek FDA Approval to Use Needle-Free Injection Device to Administer Antiretroviral Fuzeon (July 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Severe Enfuvirtide Injection Site Reactions Tied to Lack of Subcutaneous Fat (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Fuzeon (Enfuvirtide, T-20) Accelerated to Traditional Approval/Label Revisions (October 22, 2004)
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Fuzeon Recommended for CD4 Counts Over 100, Viral Loads Below 100,000 (October 2004)
Quick recap of recommendations published in the journal AIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
VIEW ALL ARTICLES
|
|
Advertisement
|